News | May 10, 2024
Alembic Pharmaceuticals posts Q4 FY24 PAT at Rs. 178.21 Cr
The company has posted net profit of Rs.615.82 crores for the Financial Year ended March 31, 2024
The company has posted net profit of Rs.615.82 crores for the Financial Year ended March 31, 2024
The company is committed to address this observation comprehensively within stipulated time
Receives 3 final and 2 tentative product approvals thus far in Q1FY25
Ashland's nutraceuticals business supplies a broad portfolio of active ingredients and formulation aids to nutritional product companies
the campaign emphasizes the brand's reliability and effectiveness in providing timely relief
Wacker Biotech US, a wholly owned subsidiary of Wacker Chemie AG, specializes in the microbial production of pDNA
Subcutaneous nivolumab has potential to be the first and only subcutaneously administered PD-1 inhibitor
Aptar Closures’ E-Disc Top securely protects against in-transit leakage while eliminating the need for liners and extra shipping preparation fees
Investing in Malaysia's largest clinic operator to expand the healthcare business
Cellectis is also eligible to receive an investigational new drug (IND) option fee and development
Subscribe To Our Newsletter & Stay Updated
